Stifel raises Teladoc Health price target to $6.5 from $5.5
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Federal Signal Reports Q3 2026 Revenue of $655.5M, EPS of $1.29
Third-quarter net income was $79.6 million. Revenue rose 18.1%, net income 16.9% and diluted EPS 16.2% from the prior-year quarter.
M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC
Peoples Bancorp Reports Third-Quarter 2026 Revenue of $119.5 Million
Revenue rose 3.8% year over year to $119.5 million. Net income increased 10.6% to $32.6 million, while diluted EPS rose to $0.91 from $0.83.
M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC
Axalta Reports Third-Quarter 2026 Revenue of $1.31 Billion
Revenue rose 1.8% year over year to $1.31 billion, while net income declined 13.6% to $95 million and diluted EPS fell 13.7% to $0.44.
M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC
Entegris CEO Says Semiconductor Demand Is Unprecedented Amid AI Boom
Entegris is seeing unprecedented semiconductor demand, Chief Executive David Reeder said, citing customers’ needs for materials and contamination control across processes and semic
M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC
Kion Publishes Q3 2026 Results Call Transcript
Kion published a transcript of its Q3 2026 results update call.
M impact | EQUITY | Oct 29, 2026, 07:20 PM UTC
Alnylam Reports Quarterly Results Through September 30
Alnylam Pharmaceuticals reported results for the quarter ended September 30. The alert provides no financial figures.
M impact | EQUITY | Oct 29, 2026, 07:15 PM UTC